🔬💉 Exciting news in the world of medicine! 🌟 Could Pfizer's Gene Therapy be the game-changer for Hemophilia B patients? 🤔 Dive into the controversy surrounding Beqvez and its potential impact on over 7,000 Americans. 💪 #GeneTherapy#HemophiliaB#MedicalInnovation
Are you ready to explore the future of rare disease treatments? Click the to learn more and join the discussion! 🚀💊 #Pfizer#HealthcareRevolution#StayInformed
article: https://buff.ly/4dijN7B
The release of gene therapies is accelerating - up 4x since 2020. Come join us for a roundtable discussion on the two major types: AAV and ASCT.
Detailed will be an exploration of development path and the impact on personalized medicine treatments. Send inquiry to info@devinebio.com to learn more on how to join us. #genetherapy#drugdiscovery#drugdevelopment#raredisease
The commercialization of cell and gene therapies (CGTs) is no easy task. With the FDA approving 7 new CGTs in 2023 alone, the total has risen to 34. But from high costs to healthcare infrastructure challenges, there’s a lot to navigate.
Read more in this blog from Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, about how AI and innovative strategies are shaping the CGT landscape.
What are the biggest roadblocks standing between patients and life-saving cell and gene therapies (CGTs)? How is AI revolutionizing cost models and transforming patient care in real time?
In their latest blog, Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, provide critical insights into the high-stakes world of CGT commercialization. They uncover the rising tide of rare disease therapies, reveal the hidden costs of scaling these cutting-edge treatments, and outline the must-have strategies companies need to thrive in an ever-evolving market – https://lnkd.in/ePF8r7Sk#CellGeneTherapy#CGT#PharmaInnovation#LifeSciences#EnvisionPharmaGroup
The commercialization of cell and gene therapies (CGTs) is no easy task. With the FDA approving 7 new CGTs in 2023 alone, the total has risen to 34. But from high costs to healthcare infrastructure challenges, there’s a lot to navigate.
Read more in this blog from Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, about how AI and innovative strategies are shaping the CGT landscape.
What are the biggest roadblocks standing between patients and life-saving cell and gene therapies (CGTs)? How is AI revolutionizing cost models and transforming patient care in real time?
In their latest blog, Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, provide critical insights into the high-stakes world of CGT commercialization. They uncover the rising tide of rare disease therapies, reveal the hidden costs of scaling these cutting-edge treatments, and outline the must-have strategies companies need to thrive in an ever-evolving market – https://lnkd.in/ePF8r7Sk#CellGeneTherapy#CGT#PharmaInnovation#LifeSciences#EnvisionPharmaGroup
The commercialization of cell and gene therapies (CGTs) is no easy task. With the FDA approving 7 new CGTs in 2023 alone, the total has risen to 34. But from high costs to healthcare infrastructure challenges, there’s a lot to navigate.
Read more in this blog from Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, about how AI and innovative strategies are shaping the CGT landscape.
What are the biggest roadblocks standing between patients and life-saving cell and gene therapies (CGTs)? How is AI revolutionizing cost models and transforming patient care in real time?
In their latest blog, Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, provide critical insights into the high-stakes world of CGT commercialization. They uncover the rising tide of rare disease therapies, reveal the hidden costs of scaling these cutting-edge treatments, and outline the must-have strategies companies need to thrive in an ever-evolving market – https://lnkd.in/ePF8r7Sk#CellGeneTherapy#CGT#PharmaInnovation#LifeSciences#EnvisionPharmaGroup
The rapid evolution of cell and gene therapies (CGTs) has been incredible, with the FDA approving seven new therapies in 2023 alone. This growth is encouraging, but we still have hurdles to overcome, from ensuring healthcare systems are prepared to handle these complex treatments to addressing high costs.
One trend catching my attention, which I was happy to write about in-depth with Kyle Felmet, is the shift toward rare diseases and autoimmune conditions fuelled by advancements in gene-editing technologies. These innovations, combined with AI's potential to navigate complex processes, optimise manufacturing and enhance patient outcomes, offer new avenues for more effective treatments and value-based pricing models.
Like any life science innovation, we must remain focused on driving patient access and affordability while equipping healthcare systems to deliver these groundbreaking CGTs.
What are the biggest roadblocks standing between patients and life-saving cell and gene therapies (CGTs)? How is AI revolutionizing cost models and transforming patient care in real time?
In their latest blog, Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, provide critical insights into the high-stakes world of CGT commercialization. They uncover the rising tide of rare disease therapies, reveal the hidden costs of scaling these cutting-edge treatments, and outline the must-have strategies companies need to thrive in an ever-evolving market – https://lnkd.in/ePF8r7Sk#CellGeneTherapy#CGT#PharmaInnovation#LifeSciences#EnvisionPharmaGroup
The commercialization of cell and gene therapies (CGTs) is no easy task. With the FDA approving 7 new CGTs in 2023 alone, the total has risen to 34. But from high costs to healthcare infrastructure challenges, there’s a lot to navigate.
Read more in this blog from Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, about how AI and innovative strategies are shaping the CGT landscape.
What are the biggest roadblocks standing between patients and life-saving cell and gene therapies (CGTs)? How is AI revolutionizing cost models and transforming patient care in real time?
In their latest blog, Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, provide critical insights into the high-stakes world of CGT commercialization. They uncover the rising tide of rare disease therapies, reveal the hidden costs of scaling these cutting-edge treatments, and outline the must-have strategies companies need to thrive in an ever-evolving market – https://lnkd.in/ePF8r7Sk#CellGeneTherapy#CGT#PharmaInnovation#LifeSciences#EnvisionPharmaGroup
Following NICE's recommendation, CASGEVY is now the first gene therapy available in Europe for treating transfusion-dependent beta thalassemia. Claire Smith and I discuss the condition, the mechanism of action of the therapy and what comes next following this landmark for CRISPR-based gene therapies - perhaps approval for the therapy's use for sickle cell disease?
CASGEVY: CRISPR/Cas9 gene therapy now available in England following NICE - National Institute for Health and Care Excellence recommendation. The MHRA "became the first health authority in the world to approve CASGEVY for the treatment of sickle cell disease ("SCD") and TDT in November 2023."
Our experts, Claire Smith and Luca Cericola, guide us through what CASGEVY is used to treat, it's approval process and what's next for "life-changing personalised medicine" like CASGEVY.
Learn more here: https://lnkd.in/eda7rRqH
The journey to commercializing Cell and Gene Therapies (CGTs) is complex, but crucial advancements are being made. In their latest blog, Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer at Envision Pharma Group, explore key trends reshaping the CGT landscape, from the growing focus on rare diseases to the impact of AI in optimizing costs and patient care.
Discover what it takes to navigate the commercialization challenges in this rapidly evolving field. Read their blog below!
What are the biggest roadblocks standing between patients and life-saving cell and gene therapies (CGTs)? How is AI revolutionizing cost models and transforming patient care in real time?
In their latest blog, Kyle Felmet, VP of Specialty Commercialization, and Paul Archer, Chief Commercial Strategy Officer, provide critical insights into the high-stakes world of CGT commercialization. They uncover the rising tide of rare disease therapies, reveal the hidden costs of scaling these cutting-edge treatments, and outline the must-have strategies companies need to thrive in an ever-evolving market – https://lnkd.in/ePF8r7Sk#CellGeneTherapy#CGT#PharmaInnovation#LifeSciences#EnvisionPharmaGroup
How could one gene therapy treat all types of hemophilia? How could it also work for inhibitor patients? Check out how GENV-HEM (AAV8.FVa) works by clicking this link: https://lnkd.in/emsuw6ve
Could Cell and Gene Therapies (CGTs) be the future? How can #Biopharma companies help close the gender care gap? What trends are transforming pharma in 2024? Find out in our Health Forward blog:
